2.01

2.90% -0.06

Bioxcel Therapeutics Inc (BTAI)

Overview News Price History Option Chain Financials Why BTAI Down? Discussions Forecast

Bioxcel Therapeutics Inc stock is traded at $2.01, with a volume of 450.51K. It is down -2.90% in the last 24 hours and up +17.54% over the past month. BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Previous Close:

$2.07

Open:

$2.14

24h Volume:

450.51K

Relative Volume:

0.47

Market Cap:

$43.96M

Revenue:

$1.38M

Net Income/Loss:

$-179.05M

P/E Ratio:

-0.3274

EPS:

-6.14

Net Cash Flow:

$-155.03M

1W Performance:

-2.90%

1M Performance:

+17.54%

6M Performance:

+13.56%

1Y Performance:

+390.36%

1-Day Range:

$1.98

$2.1731

1-Week Range:

$1.98

$2.30

52-Week Range:

$0.16

$8.08

Bioxcel Therapeutics Inc Stock (BTAI) Company Profile

Name

Bioxcel Therapeutics Inc

Sector

Healthcare (1123)

Industry

Biotechnology (627)

Phone

203-643-8060

Address

555 LONG WHARF DRIVE, NEW HAVEN, CT

Employee

Twitter

@bioxcel_tx

Next Earnings Date

2024-11-12

Latest SEC Filings

BTAI's Discussions on Twitter

Compare BTAI with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BTAI Bioxcel Therapeutics Inc	2.01	45.27M	1.38M	-179.05M	-155.03M	-6.14
VRTX Vertex Pharmaceuticals Inc	452.04	113.14B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	741.29	78.49B	14.25B	4.58B	3.88B	41.77
ARGX Argen X Se Adr	877.94	54.76B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	397.55	54.51B	3.21B	43.57M	221.36M	0.2405
INSM Insmed Inc	197.01	41.64B	447.02M	-1.18B	-906.14M	-6.1812

Bioxcel Therapeutics Inc Stock (BTAI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-21-24	Downgrade	UBS	Buy → Neutral
Aug-15-23	Downgrade	Mizuho	Buy → Neutral
Jul-17-23	Downgrade	Guggenheim	Buy → Neutral
Mar-10-23	Downgrade	Jefferies	Buy → Hold
Dec-01-22	Upgrade	Goldman	Sell → Neutral
Jul-07-22	Initiated	Mizuho	Buy
Apr-06-22	Reiterated	BofA Securities	Buy
Nov-15-21	Downgrade	Goldman	Neutral → Sell
Apr-09-21	Initiated	Berenberg	Buy
Feb-01-21	Initiated	UBS	Buy
Oct-30-20	Initiated	Goldman	Buy
Sep-02-20	Initiated	Jefferies	Buy
Aug-17-20	Reiterated	H.C. Wainwright	Buy
Jul-08-20	Reiterated	H.C. Wainwright	Buy
Jun-04-20	Initiated	Guggenheim	Buy
Apr-01-20	Initiated	BofA/Merrill	Buy
Feb-26-20	Reiterated	H.C. Wainwright	Buy
Jan-08-20	Reiterated	H.C. Wainwright	Buy
Nov-12-19	Initiated	SunTrust	Buy

View All

Bioxcel Therapeutics Inc Stock (BTAI) Latest News

Dec 12, 2025

BTAI: All proposals, including director elections and a reverse split amendment, were approved - TradingView — Track All Markets

Dec 12, 2025

Dec 06, 2025

Aug Decliners: What MACD trends signal for BioXcel Therapeutics Inc BX20 stockJuly 2025 Snapshot & Advanced Swing Trade Entry Alerts - moha.gov.vn

Dec 06, 2025

Dec 05, 2025

BioXcel Therapeutics (BTAI) price target decreased by 26.17% to 16.12 - MSN

Dec 05, 2025

Can BioXcel Therapeutics Inc. (BX20) stock sustain free cash flowQuarterly Growth Report & Weekly High Return Opportunities - Newser

Dec 05, 2025

Dec 04, 2025

What Analysts Think Is Changing The Story For BioXcel Therapeutics Now - Yahoo Finance

Dec 04, 2025

Can BioXcel Therapeutics Inc. stock beat analyst upgrades2025 Biggest Moves & Real-Time Sentiment Analysis - Newser

Dec 04, 2025

Dec 03, 2025

Is BioXcel Therapeutics Inc. (BX20) stock a fit for income portfoliosM&A Rumor & Fast Entry Momentum Alerts - Newser

Dec 03, 2025

Award-Winning Journalist Anjalee Khemlani to Host Virtual Roundtable with Leading Medical Experts to Discuss Latest Developments in Treating Acute Agitation Related to Neuropsychiatric Conditions - The Manila Times

Dec 03, 2025

Award-Winning Journalist Anjalee Khemlani to Host Virtual - GlobeNewswire

Dec 03, 2025

BioXcel Therapeutics (BTAI) hosts Dec. 8 virtual panel on at-home agitation treatment - Stock Titan

Dec 03, 2025

What is the fair value of BioXcel Therapeutics Inc. stock nowJuly 2025 Short Interest & Fast Moving Stock Watchlists - Newser

Dec 03, 2025

Dec 02, 2025

Is BioXcel Therapeutics Inc. (BX20) stock worth holding before Fed meeting2025 Winners & Losers & Technical Entry and Exit Tips - Newser

Dec 02, 2025

Nov 28, 2025

Growth Value: Will BioXcel Therapeutics Inc. stock see insider buyingSwing Trade & Stepwise Trade Signal Guides - moha.gov.vn

Nov 28, 2025

Nov 27, 2025

Can BioXcel Therapeutics Inc. stock resist market sell offsTrade Volume Report & Technical Pattern Alert System - BỘ NỘI VỤ

Nov 27, 2025

Nov 21, 2025

FDA Approves New Indication for BioXcel Therapeutics' Igalmi (BT - GuruFocus

Nov 21, 2025

Why BioXcel Therapeutics Inc. (BX20) stock could be next leaderMarket Volume Summary & AI Enhanced Trading Alerts - newser.com

Nov 21, 2025

Can BioXcel Therapeutics Inc. stock deliver consistent earnings growthEarnings Recap Summary & Consistent Return Investment Signals - newser.com

Nov 21, 2025

Is BioXcel Therapeutics Inc. stock attractive after correctionQuarterly Market Summary & Expert Approved Momentum Ideas - newser.com

Nov 21, 2025

Nov 20, 2025

Why BioXcel Therapeutics Inc. (BX20) stock is listed among top recommendationsEarnings Recap Summary & Fast Entry Momentum Trade Alerts - newser.com

Nov 20, 2025

Will BioXcel Therapeutics Inc. stock see PE expansionJuly 2025 Earnings & Long Hold Capital Preservation Tips - newser.com

Nov 20, 2025

Can BioXcel Therapeutics Inc. stock beat market expectations this quarterTrade Volume Report & Free Technical Confirmation Trade Alerts - newser.com

Nov 20, 2025

Nov 19, 2025